CD4 T Cell-mediated Protection from Lethal Influenza: Perforin and Antibody-mediated Mechanisms Give a One-two Punch
Overview
Affiliations
The mechanisms whereby CD4 T cells contribute to the protective response against lethal influenza infection remain poorly characterized. To define the role of CD4 cells in protection against a highly pathogenic strain of influenza, virus-specific TCR transgenic CD4 effectors were generated in vitro and transferred into mice given lethal influenza infection. Primed CD4 effectors conferred protection against lethal infection over a broad range of viral dose. The protection mediated by CD4 effectors did not require IFN-gamma or host T cells, but did result in increased anti-influenza Ab titers compared with untreated controls. Further studies indicated that CD4-mediated protection at high doses of influenza required B cells, and that passive transfer of anti-influenza immune serum was therapeutic in B cell-deficient mice, but only when CD4 effectors were present. Primed CD4 cells also acquired perforin (Pfn)-mediated cytolytic activity during effector generation, suggesting a second mechanism used by CD4 cells to confer protection. Pfn-deficient CD4 effectors were less able to promote survival in intact BALB/c mice and were unable to provide protection in B cell-deficient mice, indicating that Ab-independent protection by CD4 effectors requires Pfn. Therefore, CD4 effectors mediate protection to lethal influenza through at least two mechanisms: Pfn-mediated cytotoxicity early in the response promoted survival independently of Ab production, whereas CD4-driven B cell responses resulted in high titer Abs that neutralized remaining virus.
T4 Phage Displaying Dual Antigen Clusters Against H3N2 Influenza Virus Infection.
Liu S, Lin M, Zhou X Vaccines (Basel). 2025; 13(1).
PMID: 39852849 PMC: 11769387. DOI: 10.3390/vaccines13010070.
Antibody-mediated control mechanisms of viral infections.
Mackin S, Sariol A, Diamond M Immunol Rev. 2024; 328(1):205-220.
PMID: 39162394 PMC: 11661935. DOI: 10.1111/imr.13383.
Zuo Z, Mu Y, Qi F, Zhang H, Li Z, Zhou T Vaccines (Basel). 2024; 12(7).
PMID: 39066369 PMC: 11281326. DOI: 10.3390/vaccines12070731.
Kawai A, Noda M, Hirata H, Munakata L, Matsuda T, Omata D ACS Nano. 2024; 18(26):16589-16609.
PMID: 38885198 PMC: 11223497. DOI: 10.1021/acsnano.4c00278.
Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections.
Zhuang Z, Zhuo J, Yuan Y, Chen Z, Zhang S, Zhu A Vaccines (Basel). 2024; 12(5).
PMID: 38793729 PMC: 11125924. DOI: 10.3390/vaccines12050478.